GlassScriptPhysician profile
John David Whitfield
NPI 1790902013
$40,046.10
in general payments reported to CMS, 2019-2025
45 companies · $17.87 in 2025
The $17.87 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $5,131 · 2021: $5,632 · 2022: $107 · 2023: $5,023 · 2024: $5,121 · 2025: $17.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,309 · Food and Beverage: $927 · Travel and Lodging: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,308.50 |
| Food and Beverage | $927.03 |
| Travel and Lodging | $925.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $38,432.55 | 2019-2024 | Da Vinci Surgical System |
| Amgen INC. | $159.25 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.46 | 2020-2022 | |
| Janssen Biotech, INC. | $112.73 | 2020-2021 | |
| Seagen INC. | $89.36 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $85.17 | 2020-2021 | |
| Incyte Corporation | $71.21 | 2020-2021 | |
| Kyowa Kirin, INC. | $60.37 | 2020-2021 | |
| Blueprint Medicines Corporation | $56.88 | 2021 | |
| Taiho Oncology, INC. | $50.45 | 2020-2021 | |
| Coherus Oncology, INC. | $46.54 | 2020-2021 | |
| Abbvie INC. | $43.37 | 2020-2021 | |
| Puma Biotechnology, INC. | $38.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.49 | 2021 | |
| Acell, INC. | $34.02 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.